Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data.
Level 3 - non-randomized controlled study
Retrospective observational cohort study using commercial claims data without randomized controls
PubMed 40148153 · doi:10.1016/j.jacl.2025.02.001
What was done
Researchers evaluated the real-world safety profile of branded icosapent ethyl (IPE) by following new users in the MarketScan Commercial Claims database for up to 4 years. Adverse events of interest (atrial fibrillation/flutter, bleeding, constipation, and peripheral edema) were identified using ICD-10 codes. Cumulative incidences of each event were compared across real-world evidence estimates, the REDUCE-IT trial, and product labels.
What was found
The abstract reports no exact participant numbers or specific incidence percentages. It states that real-world estimates exhibited similar trends to trial-based estimates, but cumulative incidences in the claims database were consistently one-third to one-fifth of those reported in the REDUCE-IT trial or product label.
Why it matters
This study compares trial safety benchmarks to routine clinical practice, finding lower recorded rates of key adverse events among icosapent ethyl users in commercial claims.
Limits
The abstract does not report sample size, numerical rates, or statistical precision. Administrative claims data relying on ICD-10 codes are prone to substantial underreporting and misclassification of mild or moderate adverse events compared to rigorous trial surveillance.
Cited by
- contradicts FDA package inserts for prescription omega-3s Lovaza and Vascepa state they do not cause clinically significant bleeding.